skip
Praxbind® (idarucizumab) logo

Praxbind can be ordered through these approved Distributors

Available in ALL 50 States and
Over 3400+ Locations
Nationwide1*

Search our database to locate a facility in your area that has PRAXBIND available.

No Results. Please try again.

Locate a Praxbind in your area
 

Ordering Inquiries?

Contact Approved PRAXBIND Distributors

*Accurate as of 01/03/20. Boehringer Ingelheim Pharmaceuticals, Inc. cannot guarantee the availability of PRAXBIND at the facilities listed on this page. Based on the most current information available to Boehringer Ingelheim Pharmaceuticals, Inc., these institutions have purchased PRAXBIND.

Reference:

  1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.

INDICATIONS AND USAGE FOR PRAXBIND

Praxbind® (idarucizumab) is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:

  •  For emergency surgery/urgent procedures
  •  In life-threatening or uncontrolled bleeding

 

 

 

 

 

 

 

 

IMPORTANT SAFETY INFORMATION FOR PRAXBIND

WARNINGS AND PRECAUTIONS

Thromboembolic Risk

  • Dabigatran-treated patients have underlying diseases predisposing them to thromboembolic events. Reversing dabigatran therapy exposes patients to thrombotic risk. Consider resumption of anticoagulant therapy as soon as medically appropriate.

Re-elevation of Coagulation Parameters

  • Elevated coagulation parameters (e.g., activated partial thromboplastin time or ecarin clotting time) have been observed in a limited number of PRAXBIND-treated patients. If reappearance of clinically relevant bleeding together with elevated coagulation parameters is observed, or if patients requiring a second emergency surgery/urgent procedure have elevated coagulation parameters, an additional full dose may be considered.

Hypersensitivity Reactions

  • There is insufficient clinical experience evaluating risk of hypersensitivity to idarucizumab, but a possible relationship could not be excluded. Risk of hypersensitivity (e.g., anaphylactoid reaction) to idarucizumab or excipients needs to be weighed cautiously against the potential benefit. If serious allergic reaction occurs, immediately discontinue PRAXBIND and institute appropriate treatment.

Risk in Patients With Hereditary Fructose Intolerance

  • PRAXBIND contains 4 g sorbitol as an excipient. When prescribing PRAXBIND in patients with hereditary fructose intolerance, consider the total daily amount of sorbitol/fructose consumption from all sources, as serious adverse reactions (e.g., hypoglycemia, hypophosphatemia, metabolic acidosis, increase in uric acid, acute liver failure, and death) may occur.

 

ADVERSE REACTIONS

  • The most frequently reported adverse reaction in ≥5% of idarucizumab-treated healthy volunteers was headache (5%). The most frequently reported adverse reactions in ≥5% of patients were constipation (7%) and nausea (5%).

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation

  •  PRAXBIND should be given to a pregnant woman only if clearly needed. Caution should be exercised when PRAXBIND is administered to a nursing woman.

CL-PB-100001 April 2018

Please click here for full Prescribing Information for PRAXBIND.